Journal: Cell reports
Article Title: The C-terminal disordered loop domain of Apc8 unlocks APC/C mitotic activation.
doi: 10.1016/j.celrep.2024.114262
Figure Lengend Snippet: Figure 5. Apc8-L influences Apc1-300L phosphorylation via direct Xe-p9/Cks2 recruitment (A and B) Workflow of the in situ phosphorylation assay (A). (B) Wild-type rAPC/Cs and rAPC/C with mutant Apc8, each with cleavable ALFA-Apc1-300L, were phosphorylated using anaphase extracts, or control interphase extracts, for 1 h. For an unmodified control, rAPC/C not incubated with extract is shown as ‘‘negative.’’ Immobilized rAPC/Cs were washed harshly before ALFA-Apc1-300Ls were excised by HRV-3C protease. Reactions were analyzed by SDS-PAGE and immunoblotting: 3C-x-Apc1 and 3C-x-a300L denote the Apc1 HRV-3C cleavage products. (C–F) In vitro Xe-p9/Cks2 binding assay with bacterially purified MBP-tagged Apc8-L fragments. Equal amounts of pre-phosphorylated Apc8-loop proteins were incubated with purified Xe-p9/Cks2 for 30 min. Phosphorylation-dependent interactions were analyzed by SDS-PAGE and immunoblotting. Representative images (C and E) and quantitative analysis (D and F) (n = 3). His-Xe-p9 levels were first normalized to MBP eluate levels, and then intensities of MBP-Apc8-L-WT were arbitrarily set to 1.0. Error bars, SD, one-way ANOVA with Tukey’s post-hoc test; ***p % 0.001. (G) Anaphase phosphorylation assay assessing APC/C phospho-activation upon Apc8-L deletion. Interphase Xenopus extracts were prepared, and endogenous APC/Cs were depleted. Non-degradable cyclin B (CycBD167) was added to trigger anaphase entry, marked as time point T0. Samples were taken at the indicated time points. Phosphorylation status was analyzed by SDS-PAGE and immunoblotting for Apc1 and Apc8 subunits, as well as three phospho-specific antibodies targeting CDK-favored phospho-residues within Apc1-300L.
Article Snippet: Purified MBP-tagged Apc8 fragments were incubated with amylose resin (NEB) (400 pmol MBP-tagged proteins on 5 mL packed resin in 400 mL in 1x XBcsf containing 0.1% NP40) at 4 C for 1–2 h with end-over-end rotation (15 rpm).
Techniques: Phospho-proteomics, In Situ, Mutagenesis, Control, Incubation, SDS Page, Western Blot, In Vitro, Binding Assay, Activation Assay